CoChat

Mild Cognitive Impairment: the Manchester consensus

Open access
Dunne, Ross A, Aarsland, Dag, O’Brien, John T, Ballard, Clive, Banerjee, Sube, Fox, Nick C, Isaacs, Jeremy D, Underwood, Benjamin R, Perry, Richard J, Chan, Dennis, Dening, Tom, Thomas, Alan J, Schryer, Jeffrey, Jones, Anne-Marie, Evans, Alison R, Alessi, Charles, Coulthard, Elizabeth J, Pickett, James, Elton, Peter, Jones, Roy W, Mitchell, Susan, Hooper, Nigel, Kalafatis, Chris, Rasmussen, Jill G C, Martin, Helen, Schott, Jonathan M, Burns, Alistair · 2021 · Age and Ageing
Cited by 216

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

Given considerable variation in diagnostic and therapeutic practice, there is a need for national guidance on the use of neuroimaging, fluid biomarkers, cognitive testing, follow-up and diagnostic terminology in mild cognitive impairment (MCI). MCI is a heterogenous clinical syndrome reflecting a change in cognitive function and deficits on neuropsychological testing but relatively intact activities of daily living. MCI is a risk state for further cognitive and functional decline with 5–15% of people developing dementia per year. However, ~50% remain stable at 5 years and in a minority, symptoms resolve over time. There is considerable debate about whether MCI is a useful clinical diagnosis, or whether the use of the term prevents proper inquiry (by history, examination and investigations) into underlying causes of cognitive symptoms, which can include prodromal neurodegenerative disease, other physical or psychiatric illness, or combinations thereof. Cognitive testing, neuroimaging and fluid biomarkers can improve the sensitivity and specificity of aetiological diagnosis, with growing evidence that these may also help guide prognosis. Diagnostic criteria allow for a diagnosis of Alzheimer’s disease to be made where MCI is accompanied by appropriate biomarker changes, but in practice, such biomarkers are not available in routine clinical practice in the UK. This would change if disease-modifying therapies became available and required a definitive diagnosis but would present major challenges to the National Health Service and similar health systems. Significantly increased investment would be required in training, infrastructure and provision of fluid biomarkers and neuroimaging. Statistical techniques combining markers may provide greater sensitivity and specificity than any single disease marker but their practical usefulness will depend on large-scale studies to ensure ecological validity and that multiple measures, e.g. both cognitive tests and biomarkers, are widely available for clinical use. To perform such large studies, we must increase research participation amongst those with MCI.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ageing/afaa228

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 216

Metadata

Authors
Dunne, R. A., Aarsland, D., O’Brien, J. T., Ballard, C., Banerjee, S., Fox, N. C., Isaacs, J. D., Underwood, B. R., Perry, R. J., Chan, D., Dening, T., Thomas, A. J., Schryer, J., Jones, A.-M., Evans, A. R., Alessi, C., Coulthard, E. J., Pickett, J., Elton, P., Jones, R. W., Mitchell, S., Hooper, N., Kalafatis, C., Rasmussen, J. G. C., Martin, H., Schott, J. M., & Burns, A.
Venue
Age and Ageing
Published
2020-11-17
Volume
50
Issue
1
Pages
72-80
ISSN
  • 0002-0729 (ISSN-L)
  • 1468-2834
OpenAlex
W3082308014
Cited by
216
References
13
FWCI
11.33
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.